Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AngloGold Ashanti Limited (AU) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

AngloGold Ashanti LimitedTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

AngloGold Ashanti Limited vs Ginkgo Bioworks Holdings Inc — how do they compare? AngloGold Ashanti Limited trades at $97.6 (market cap $49.28B), while Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M). The key difference: AngloGold Ashanti Limited is far larger — about 97.4× Ginkgo Bioworks Holdings Inc's market cap, and AngloGold Ashanti Limited pays a 4.64% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

AUDNA
Market Cap
$49.28B$505.73M
Sector
Basic MaterialsHealth
52-Week High
$128.26$16.14
52-Week Low
$52.15$5.48
Enterprise Value
$48.29B$607.68M
Dividend Yield
4.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AngloGold Ashanti Limited

AngloGold Ashanti (AU) trades at $97.89, up 0.66% with strong bullish momentum from moving averages. The stock shows robust fundamentals with 32.19% net income margin and 46.5% ROE, supported by rising gold prices and production growth. Recent Q2 2026 earnings beat expectations with $727 million free cash flow, while the company maintains a $2 billion buyback program. Technical indicators show overbought conditions with RSI at 79.27, but institutional interest remains strong with multiple recent position increases.

Outlook remains positive with analyst consensus target of $120.33 (23% upside) and 64% buy ratings. Key catalysts include H2 production growth and shareholder returns, though risks include gold price volatility and operational challenges. The stock trades at reasonable valuations (P/E 13.06, EV/EBITDA 7.58) with improving balance sheet strength (debt-to-asset ratio declining to 15.59%).

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.

DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.

Returns comparison

Trailing returns across standard periods

About AngloGold Ashanti Limited

Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.

Read more on AU

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA